Taoscare recalled 3 boxes of motion sickness patches on October 9, 2025. The product was marketed without an approved NDA/ANDA. Consumers should stop using the patches immediately and seek guidance.
Marketed Without an Approved NDA/ANDA
Consumers and healthcare providers should stop using this product immediately. Contact ibspot or your healthcare provider for guidance. Notification method: E-Mail
The recall involves Taoscare Motion Sickness Patches sold in 36-count boxes. The product was distributed in Wyoming and Virginia.
These patches were marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). This raises concerns about their safety and efficacy.
There are no reported incidents associated with this product at this time. However, the lack of regulatory approval poses potential risks.
Stop using the Taoscare Motion Sickness Patches immediately. Contact ibspot or your healthcare provider for further guidance.
For more information, visit the FDA website or contact ibspot via email for assistance on the recall.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.